Investor Relations

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

More News

Aclarion Publishes 2026 Shareholder Letter from the Chairman

February 5, 2026
2026 Annual Shareholder Letter from the Chairman

February 5, 2026
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

February 3, 2026